{
    "organizations": [],
    "uuid": "3f0519a032980dd2dde160055c7f7d1f0d9997d3",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-asit-biotech-announces-validation/brief-asit-biotech-announces-validation-of-its-patient-blood-cell-in-vitro-selection-platform-idUSFWN1S80RE",
    "ord_in_thread": 0,
    "title": "BRIEF-Asit Biotech Announces Validation Of Its Patient Blood Cell In Vitro Selection Platform",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "May 2 (Reuters) - ASIT BIOTECH SA:\n* ANNOUNCES VALIDATION OF ITS PATIENT BLOOD CELL IN VITRO SELECTION PLATFORM FOR ITS NEW PRODUCT CANDIDATES AND FILING OF A EUROPEAN PATENT APPLICATION\n* DURING A FIRST PHASE III TRIAL DURING A FIRST PHASE III TRIAL (BTT009) CLINICAL EFFICACY OF GP-ASIT+ WAS STATISTICALLY SIGNIFICANTLY CONFIRMED\n* EFFICACY WAS SUPPORTED BY IMMUNOLOGICAL RESULTS OBTAI EFFICACY WAS SUPPORTED BY IMMUNOLOGICAL RESULTS OBTAINED ON GROUP OF PATIENTS TREATED AT GHENT UNIVERSITY HOSPITAL\n* SELECTION METHOD DEVELOPED BY ASIT BIOTECH HAS BEEN CLAIMED IN A PATENT APPLICATION FILED IN EUROPE ON 30 APRIL 2018\n* PATENT SAFEGUARDS ASIT BIOTECHâ€™S FUTURE DEVELOPMENTS Source text for Eikon: Further company coverage: (Gdynia Newsroom)\n ",
    "published": "2018-05-02T13:38:00.000+03:00",
    "crawled": "2018-05-03T12:34:13.018+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "may",
        "reuters",
        "asit",
        "biotech",
        "sa",
        "announces",
        "validation",
        "patient",
        "blood",
        "cell",
        "vitro",
        "selection",
        "platform",
        "new",
        "product",
        "candidate",
        "filing",
        "european",
        "patent",
        "application",
        "first",
        "phase",
        "iii",
        "trial",
        "first",
        "phase",
        "iii",
        "trial",
        "btt009",
        "clinical",
        "efficacy",
        "statistically",
        "significantly",
        "confirmed",
        "efficacy",
        "supported",
        "immunological",
        "result",
        "obtai",
        "efficacy",
        "supported",
        "immunological",
        "result",
        "obtained",
        "group",
        "patient",
        "treated",
        "ghent",
        "university",
        "hospital",
        "selection",
        "method",
        "developed",
        "asit",
        "biotech",
        "claimed",
        "patent",
        "application",
        "filed",
        "europe",
        "april",
        "patent",
        "safeguard",
        "asit",
        "biotech",
        "future",
        "development",
        "source",
        "text",
        "eikon",
        "company",
        "coverage",
        "gdynia",
        "newsroom"
    ]
}